Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data on each of its clinical-stage anticancer compounds at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) being held April 12-16 in San Diego, CA. Sunesis has built a portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell cycle and survival signaling.

Data from non-clinical studies of SNS-595, SNS-032 and SNS-314 will be presented in five posters and one oral presentation during the AACR Meeting. New insights on the mechanism of action and anticancer activity of SNS-595, Sunesis' lead compound, will be featured on Monday, April 14, 2008. SNS-595 is a novel naphthyridine analog structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 both selectively intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b combination clinical trial with cytarabine in relapsed/refractory acute myeloid leukemia are both ongoing.

SNS-595 Poster Presentations

Monday, April 14, 2008

-- SNS-595 is a potent anti-tumor agent that has a dual mechanism of

action: DNA intercalation and site-selective topoisomerase II poisoning

Session: Stress Responses

Abstract #1860

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

-- Sensitivity to SNS-595 is related to activation of double strand DNA

break repair pathways including homologous recombination

Session: Stress Responses

Abstract #1859

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

-- Ex vivo activity of SNS-595 against biopsies of acute myeloid leukemia,

triple negative breast and ovarian cancers supports ongoing and

potential clinical indications

Session: Novel Drug Targets, Agents and Mechanisms

Abstract #2830

1:00 p.m. - 5:00 p.m. Exhibit Hall B-F, San Diego Convention Center

Suzanne Trudel, MSc, M.D., Assistant Professor, Princess Margaret Hospital, University Health Network, will provide an oral presentation on SNS-032's preclinical activity in multiple myeloma as part of a minisymposium on Tuesday, April 15, 2008. In addition, translational research data detailing the relationship between SNS-032's mechanism and its activity in certain types of cancer will be presented in a poster. SNS-032, a potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory chronic lymphocytic leukemia or multiple myeloma.

SNS-032 Oral Presentation

Tuesday, April 15, 2008

-- SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates

preclinical activity in human multiple myeloma

Minisymposium: Novel Genomic Approaches, Drugs, Targets, and Strategies

Abstract #4972

4:55 p.m. to 5:10 p.m. Room 30A-C, San Diego Convention Center

SNS-032 Poster Presentation

Sunday, April 13, 2008

-- SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7, and 9,

blocks transcription of cyclin D1 and Mcl-1, causing cell death in

mantle cell lymphoma cell lines

Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Abstract #756

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

Preclinical data providing new details on SNS-314's anti-tumor activity will be presented Wednesday, April 16, 2008. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

SNS-314 Poster Presentation

Wednesday, April 16, 2008

-- SNS-314, a potent inhibitor of Aurora kinases, has preclinical

anti-activity and induces apoptosis

Session: Heat Shock Protein Inhibitors, Aurora Kinase and other Mitotic

Inhibitors

Abstract #5648

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in the ... Okaloosa County Emergency Medical Services (EMS) consisting of ... LT2 van. Quality Emergency Vehicles in Lecanto, FL ... sale.  This is the latest in Demers, ongoing expansion of ... at Demers. --> Benoit LaFortune , Executive Vice ...
(Date:2/12/2016)...   HeartWare International, Inc . (NASDAQ: HTWR ... discuss its financial results for the three and 12 ... 2016 at 8:00 a.m. ET.  The company plans to ... and webcast.  On the conference call and webcast, management ... fourth quarter and business outlook.   --> ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology:
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut ... Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the ... the big event. The invitation-only gifting suite, held this year at the W Hollywood ...
(Date:2/12/2016)... NV (PRWEB) , ... February 12, 2016 , ... Fisher ... Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and ... House at the VA Southern Nevada Healthcare System. This will be the first ...
(Date:2/12/2016)... ... 12, 2016 , ... Young Asset Protection, a full service ... the latest charity campaign in their community enrichment program. Art Expression utilizes after-school ... cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression is ...
(Date:2/12/2016)... New York, NY (PRWEB) , ... February 12, ... ... latest edition of “Revolutionizing Cancer Care.” , The print component of ... in Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation ...
Breaking Medicine News(10 mins):